These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2031266)

  • 1. Amplification of the graft-versus-leukemia effect in man by interleukin-2.
    Verdonck LF; van Heugten HG; Giltay J; Franks CR
    Transplantation; 1991 May; 51(5):1120-4. PubMed ID: 2031266
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of leukemic relapse following unrelated umbilical cord blood transplantation with interleukin-2: potential for augmenting graft-versus-leukemia and graft-versus-host effects with cytokines.
    Goldberg SL; Pecora AL; Rosenbluth RJ; Jennis AA; Preti RA
    Bone Marrow Transplant; 2000 Aug; 26(3):353-5. PubMed ID: 10967580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloblastic leukaemia: graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease.
    Boughton BJ; Simpson AW
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):1-6. PubMed ID: 10390074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of immunotherapy in bone marrow transplantation for acute myeloid leukemia.
    Prentice HG; Macdonald ID; Hamon MD
    Prog Clin Biol Res; 1994; 389():239-43. PubMed ID: 7700907
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.
    Foa R; Meloni G; Tosti S; Novarino A; Fenu S; Guarini A; Cardona S; Gillio Tos A; Gavosto F; Mandelli F
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():98-102. PubMed ID: 2202476
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
    Blaise D; Attal M; Reiffers J; Michallet M; Bellanger C; Pico JL; Stoppa AM; Payen C; Marit G; Bouabdallah R; Sotto JJ; Rossi JF; Brandely M; Hercend T; Maraninchi D
    Eur Cytokine Netw; 2000 Mar; 11(1):91-8. PubMed ID: 10705305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 2 treatment in acute myelogenous leukemia.
    Mandelli F; Vignetti M; Tosti S; Andrizzi C; Foa R; Meloni G
    Stem Cells; 1993 Jul; 11(4):263-8. PubMed ID: 8401249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-2 for the treatment of acute leukemias.
    Meloni G; Foa R; Capria S; Tosti S; Vignetti M; Gavosto F; Mandelli F
    Leukemia; 1992; 6 Suppl 2():28-30. PubMed ID: 1578937
    [No Abstract]   [Full Text] [Related]  

  • 10. Induction of cutaneous 'graft-versus-host like' reaction by recombinant IL-2 after autologous bone marrow transplantation.
    Costello R; Blaise D; Jacquemier J; Monges G; Stoppa AM; Viens P; Olive D; Bouabdallah M; Brandely ; Gastaut JA
    Bone Marrow Transplant; 1995 Jul; 16(1):199-200. PubMed ID: 7581125
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy.
    Margolin K; Forman SJ
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S33-8. PubMed ID: 10685656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunophenotypic profile of peripheral blood eosinophils in acute graft-vs.-host disease.
    Rumi C; Rutella S; Bonini S; Bonini S; Lambiase A; Sica S; Puggioni P; Salutari P; Etuk B; Leone G
    Exp Hematol; 1998 Feb; 26(2):170-8. PubMed ID: 9472806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.
    Klingemann HG; Eaves CJ; Barnett MJ; Eaves AC; Hogge DE; Nantel SH; Reece E; Shepherd JD; Sutherland HJ; Phillips GL
    Bone Marrow Transplant; 1994 Sep; 14(3):389-96. PubMed ID: 7994260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation.
    Dermime S; Mavroudis D; Jiang YZ; Hensel N; Molldrem J; Barrett AJ
    Bone Marrow Transplant; 1997 May; 19(10):989-99. PubMed ID: 9169643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice.
    Vourka-Karussis U; Karussis D; Ackerstein A; Slavin S
    Exp Hematol; 1995 Mar; 23(3):196-201. PubMed ID: 7875238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of immunotherapy in the treatment of acute myeloblastic leukemia: from allogeneic bone marrow transplantation to the application of interleukin 2.
    Prentice HG; Macdonald ID; Hamon MD
    Cancer Treat Res; 1993; 64():121-34. PubMed ID: 8095790
    [No Abstract]   [Full Text] [Related]  

  • 18. Interleukin-2 in autologous bone marrow transplantation.
    Charak BS
    Natl Med J India; 1993; 6(1):19-22. PubMed ID: 8453356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia.
    Kloosterman TC; Tielemans MJ; Martens AC; van Bekkum DW; Hagenbeek A
    Bone Marrow Transplant; 1994 Jul; 14(1):15-22. PubMed ID: 7951103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of high-dose recombinant interleukin 2 after autologous bone marrow transplantation in patients with neuroblastoma: toxicity, efficacy and survival. A Lyon-Marseille-Curie-east of France Group Study.
    Michon J; Négrier S; Coze C; Mathiot C; Frappaz D; Oskam R; Pacquement H; Quintana E; Bouffet E; Bernard JL
    Prog Clin Biol Res; 1994; 385():293-300. PubMed ID: 7972223
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.